Hepatic Carcinoma Clinical Trial
Official title:
Microwave Ablation Combined With Simultaneous TACE Plus Sintilimab for Unresectable HCC.
Efficacy and Safety of Locoregional treatments Combined With PD-1 Inhibitor in Patients With Unresectable Hepatocellular Carcinoma.
Hepatocellular carcinoma is the most frequent primary and ranked as the sixth most common neoplasm and the third leading cause of cancer death. Percutaneous ablation and TACE are the effective locoregional treatments for the patient with HCC. Moreover, some studies suggested that TACE combined with ablation could further improve the survival rate and reduce the post-operation complication. Although PD-1 inhibitor was approved by FDA for HCC, the latest RCT indicated that no significant difference was found in the ORR and PFS between the groups of PD-1 inhibitor and Sorafenib. Therefore, this study aims to assess the efficacy and safety of microwave ablation combined with simultaneous TACE plus PD-1 inhibitor for the non-resectable HCC. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03253250 -
The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resection
|
Phase 4 | |
| Terminated |
NCT01760616 -
Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy
|
Phase 4 | |
| Active, not recruiting |
NCT04682847 -
Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
|
||
| Not yet recruiting |
NCT03149523 -
Exhaustive Genetic and Immunological Characterization of Colon, Kidney and Liver Tumors
|
N/A | |
| Recruiting |
NCT05009550 -
ESP Block on Patient Outcomes in Patients With Liver Tumor Undergoing Radiofrequency Ablation
|
N/A | |
| Recruiting |
NCT06342414 -
An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
|
||
| Recruiting |
NCT03132740 -
Impact of Three-dimensional Visualization on Operation Strategy and Complications for Complex Hepatic Carcinoma
|
||
| Completed |
NCT03164382 -
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma
|
Phase 3 | |
| Completed |
NCT03572582 -
Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma
|
Phase 2 | |
| Completed |
NCT04266548 -
Arterial Base Fluorescence Segmental Positive Staining
|
N/A | |
| Recruiting |
NCT03013712 -
A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01350726 -
Functional-three-dimensional Reconstruction of Liver by 99MTc-GSA-SPECT Scan
|
N/A | |
| Completed |
NCT06245798 -
Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension
|
||
| Recruiting |
NCT06311396 -
Development of a Neuronal Microscope
|
N/A | |
| Completed |
NCT02352935 -
Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function
|
N/A | |
| Completed |
NCT02332551 -
Percutaneous Irreversible Electroporation to Treat Liver Cancer Close to the Gallbladder
|
N/A | |
| Completed |
NCT02834780 -
Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
|
Phase 1 | |
| Not yet recruiting |
NCT06182865 -
A Study of Ga-68 Dolacga to Evaluate Liver Reserve Function in Patients With HCC Before and After Proton Therapy
|
N/A | |
| Completed |
NCT05007548 -
to Assess the Accuracy and Reliability of the Ga68-Dolacga Positron Emission Tomography Compared to Computer Tomography Volumetry and Indocyanine Green Retention Test for Measurement of Liver Reserve
|
Phase 2 | |
| Completed |
NCT03163186 -
Transradial Versus Transfemoral Arterial Access in Liver Cancer Embolization: Randomized Trial to Assess Patient Outcomes and Satisfaction (BEST ACCESS Trial).
|
N/A |